A novel mouse model of calcific aortic valve stenosis

被引:0
|
作者
Qian, Ningjing [1 ,2 ,3 ]
Wang, Yaping [1 ,2 ,3 ]
Hu, Wangxing [1 ,2 ,3 ]
Cao, Naifang [1 ,2 ,3 ]
Qian, Yi [2 ,3 ,4 ]
Chen, Jinyong [1 ,2 ,3 ]
Fang, Juan [5 ]
Xu, Dilin [1 ,2 ,3 ]
Hu, Haochang [1 ,2 ,3 ]
Yang, Shuangshuang [1 ,2 ,3 ]
Zhou, Dao [1 ,2 ,3 ]
Dai, Hanyi [1 ,2 ,3 ]
Wei, Dongdong [4 ]
Wang, Jian'an [1 ,2 ,3 ,6 ]
Liu, Xianbao [1 ,2 ,3 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 2, Dept Cardiol, Sch Med, Hangzhou, Peoples R China
[2] State Key Lab Transvasc Implantat Devices, Hangzhou, Peoples R China
[3] Cardiovasc Key Lab Zhejiang Prov, Hangzhou, Peoples R China
[4] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Cardiovasc Surg, Hangzhou, Peoples R China
[5] Zhejiang Univ, Affiliated Hosp 2, Dept Endocrinol, Sch Med, Hangzhou, Peoples R China
[6] Zhejiang Univ, Binjiang Inst, Hangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
animal model; calcific aortic valve stenosis; valve calcification; DISEASE;
D O I
10.1002/ame2.12393
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
BackgroundCalcific aortic valve stenosis (CAVS) is one of the most challenging heart diseases in clinical with rapidly increasing prevalence. However, study of the mechanism and treatment of CAVS is hampered by the lack of suitable, robust and efficient models that develop hemodynamically significant stenosis and typical calcium deposition. Here, we aim to establish a mouse model to mimic the development and features of CAVS.MethodsThe model was established via aortic valve wire injury (AVWI) combined with vitamin D subcutaneous injected in wild type C57/BL6 mice. Serial transthoracic echocardiography was applied to evaluate aortic jet peak velocity and mean gradient. Histopathological specimens were collected and examined in respect of valve thickening, calcium deposition, collagen accumulation, osteogenic differentiation and inflammation.ResultsSerial transthoracic echocardiography revealed that aortic jet peak velocity and mean gradient increased from 7 days post model establishment in a time dependent manner and tended to be stable at 28 days. Compared with the sham group, simple AVWI or the vitamin D group, the hybrid model group showed typical pathological features of CAVS, including hemodynamic alterations, increased aortic valve thickening, calcium deposition, collagen accumulation at 28 days. In addition, osteogenic differentiation, fibrosis and inflammation, which play critical roles in the development of CAVS, were observed in the hybrid model.ConclusionsWe established a novel mouse model of CAVS that could be induced efficiently, robustly and economically, and without genetic intervention. It provides a fast track to explore the underlying mechanisms of CAVS and to identify more effective pharmacological targets. Here we established a novel mouse model of calcific aortic valve stenosis that could be induced efficiently, robustly and economically, and without genetic intervention. Via induction by wire injury combined with vitamin D injection, the model allowed wild type mice to develop the typical features of calcific aortic valve stenosis, calcium deposition in valve leaflets and hemodynamically significant stenosis, as well as histopathological changes in multi-dimensions.image
引用
收藏
页码:523 / 532
页数:10
相关论文
共 50 条
  • [1] PALMD as a novel target for calcific aortic valve stenosis
    Bosse, Yohan
    Mathieu, Patrick
    Theriault, Sebastien
    CURRENT OPINION IN CARDIOLOGY, 2019, 34 (02) : 105 - 111
  • [2] Pathogenesis of calcific aortic valve stenosis
    Kaden, Jens J.
    HERZ, 2006, 31 (07) : 620 - 628
  • [3] A Novel Mouse Model of Aortic Valve Stenosis Induced by Direct Wire Injury
    Honda, Shintaro
    Miyamoto, Takuya
    Watanabe, Tetsu
    Narumi, Taro
    Kadowaki, Shinpei
    Honda, Yuki
    Otaki, Yoichiro
    Hasegawa, Hiromasa
    Netsu, Shunsuke
    Funayama, Akira
    Ishino, Mitsunori
    Nishiyama, Satoshi
    Takahashi, Hiroki
    Arimoto, Takanori
    Shishido, Tetsuro
    Miyashita, Takehiko
    Kubota, Isao
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2014, 34 (02) : 270 - 278
  • [4] Osseous and chondromatous metaplasia in calcific aortic valve stenosis
    Torre, Matthew
    Hwang, David H.
    Padera, Robert F.
    Mitchell, Richard N.
    VanderLaan, Paul A.
    CARDIOVASCULAR PATHOLOGY, 2016, 25 (01) : 18 - 24
  • [5] Calcific Aortic Valve Stenosis and Atherosclerotic Calcification
    Barros de Oliveira Sa, Michel Pompeu
    Cavalcanti, Luiz Rafael P.
    Perazzo, Alvaro M.
    Gomes, Rafael A. F.
    Clavel, Marie-Annick
    Pibarot, Philippe
    Biondi-Zoccai, Giuseppe
    Zhigalov, Konstantin
    Weymann, Alexander
    Ruhparwar, Arjang
    Lima, Ricardo Carvalho
    CURRENT ATHEROSCLEROSIS REPORTS, 2020, 22 (02)
  • [6] Development and validation of a new prediction model for calcific aortic valve stenosis
    Chen, Jun-Yu
    Zhu, Ming-Zhen
    Xiong, Tao
    Wang, Zi-Yao
    Chang, Qing
    JOURNAL OF THORACIC DISEASE, 2022, 14 (10) : 4044 - 4054
  • [7] Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve Stenosis
    Burdeynaya, Anna L. L.
    Afanasieva, Olga I. I.
    Ezhov, Marat V. V.
    Klesareva, Elena A. A.
    Saidova, Marina A. A.
    Pokrovsky, Sergey N. N.
    DISEASES, 2023, 11 (01)
  • [8] Lipoprotein(a) as Orchestrator of Calcific Aortic Valve Stenosis
    Schnitzler, Johan G.
    Ali, Lubna
    Groenen, Anouk G.
    Kaiser, Yannick
    Kroon, Jeffrey
    BIOMOLECULES, 2019, 9 (12)
  • [9] Antiphospholipid antibodies in patients with calcific aortic valve stenosis
    Plunde, Oscar
    Svenungsson, Elisabet
    Ferrannini, Giulia
    Franco-Cereceda, Anders
    Back, Magnus
    RHEUMATOLOGY, 2023, 62 (03) : 1187 - 1196
  • [10] Impact of Lipoprotein(a) on Valvular and Cardiovascular Outcomes in Patients With Calcific Aortic Valve Stenosis
    Girard, Arnaud S.
    Paulin, Audrey
    Manikpurage, Hasanga D.
    Lajeunesse, Emma
    Clavel, Marie-Annick
    Pibarot, Philippe
    Krege, John H.
    Mathieu, Patrick
    Theriault, Sebastien
    Arsenault, Benoit J.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2025, 14 (06):